指南与共识乳腺癌支持与姑息治疗

ASCO指南更新:乳腺癌初始治疗后的随访与监测

Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.
指南 / 共识 · J Clin Oncol · 2026-07-16

ASCO专家组基于系统综述和改良Delphi共识制定乳腺癌初始治疗后随访与监测推荐。仅1项RCT构成乳腺X线监测推荐的证据基础,无RCT评估基于复发风险的随访策略差异。指南推荐定期病史、体格检查和乳腺X线,可虚拟或面对面访视,高危患者(如局部晚期或新辅助化疗后残留)需更密切监测。

要点

  • 推荐定期病史、体格检查和乳腺X线用于乳腺癌随访
  • 虚拟或面对面访视均可选择
  • 局部晚期或新辅助化疗后残留等高危患者需更密切监测

核心结论

  • 推荐定期病史、体格检查和乳腺X线用于乳腺癌初始治疗后随访。
  • 可提供虚拟或面对面访视。
  • 局部晚期或新辅助化疗后残留等高复发风险患者需更密切监测。
  • 指南提供血液生物标志物和补充影像学使用的推荐。

研究设计与样本

  • ASCO召集专家组,基于系统综述和正式共识过程制定推荐。
  • 仅识别1项RCT构成乳腺X线监测推荐的证据基础。
  • 未识别评估不同随访方法按复发风险分层的RCT。
  • 因证据缺乏,采用改良Delphi共识法生成推荐。

主要发现

  • 系统综述仅识别1项RCT用于乳腺X线监测推荐。
  • 无RCT评估早期乳腺癌患者按复发风险不同随访方法。
  • 基于有限证据形成共识推荐。

关键数值与推荐

  • 推荐定期病史、体格检查和乳腺X线用于乳腺癌随访。
  • 虚拟或面对面访视均可提供。
  • 局部晚期疾病或新辅助化疗后残留等高风险患者需更密切监测。

临床怎么用

  • 临床实践中对乳腺癌初始治疗后患者定期进行病史、体格检查和乳腺X线。
  • 可根据情况选择虚拟或面对面访视。
  • 识别局部晚期或新辅助化疗后残留等高危患者并加强监测。

局限性

  • 仅1项RCT构成乳腺X线监测推荐的证据基础。
  • 无RCT评估按复发风险分层的不同随访方法。
  • 证据缺乏,推荐主要基于改良Delphi共识。
  • 指南将在额外循证工具可用时更新以更好个体化监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the https://www.asco.org/practice-patients/guidelines/guideline-methodology. ASCO Guidelines follow the https://www.asco.org/about-asco/legal/conflict-interest-coi.Clinical Practice Guidelines and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more. PURPOSE: To offer clinicians recommendations concerning breast cancer follow-up and surveillance after primary treatment. METHODS: ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process. RESULTS: One randomized controlled trial (RCT) was identified and formed the evidentiary basis for the surveillance mammography guideline recommendation. No RCTs were identified that evaluated different follow-up approaches by risk of relapse in patients treated for early-stage breast cancer. Given the dearth of evidence identified in the systematic review of the literature, formal modified Delphi consensus-based recommendations were generated. RECOMMENDATIONS: The guideline offers recommendations on the role of a risk-based approach to the frequency and intensity of follow-up among patients with breast cancer in the adjuvant setting. Regular history, physical examination, and mammography are recommended for breast cancer follow-up. Either virtual or in-person visits can be offered. Certain patients at a high risk of cancer recurrence warrant closer surveillance, such as those patients with locally advanced disease or residual disease following neoadjuvant chemotherapy. Recommendations on the use of blood-based biomarkers and supplemental imaging are provided. Guideline recommendations will be updated once additional evidence-based tools become available to better individualize surveillance.Additional information is available at www.ascopubs.org/topics/asco-guidelines/breast-cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Nahleh Z, Alfano CM, Somerfield MR, et al. Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update. J Clin Oncol. 2026. PMID: 42462191. doi:10.1200/JCO-26-01700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。